OSAKA -- Japanese drugmaker Shionogi announced on Monday that Chinese authorities have accepted its application filing to manufacture and sell Cefiderocol, used to treat antimicrobial-resistant infections for which existing antibiotics are ineffective.
A Chinese group company had been conducting Phase 3 clinical trials in China. After efficacy and safety were demonstrated, it applied for approval from authorities.






.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)